🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD

Recruitingn/aAges 50 Years - anyAllBeijing Anlong Biopharmaceutical Co., Ltd.
NCT06718816 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study is designed to evaluate long-term safety and efficacy of AL-001 ophthalmic injection following suprachoroidal space(SCS) administration in subjects with wAMD. Eligible patients, are those who were previously enrolled in a clinical study in which they received a single dose of AL-001 administered via suprachoroidal space injection.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * The subjects enrolled in AL-001 study and received AL-001 ophthalmic injection. * The subject or their legal representative agrees to participate in this study and signs a written ICF. * The subjects are willing and able to follow planned visits and procedures. Exclusion Criteria: * None
💊

What it tests

  • Not listed
📍

Where

1 site
Chinese Academy of Medical Sciences & Peking Union Hospital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy